Incomplete Freund's adjuvant
- Generic Name
- Incomplete Freund's adjuvant
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- Y9DQK7DB5U
- Associated Conditions
- -
- Associated Therapies
- -
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-03-29
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00080353
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
- First Posted Date
- 2003-04-28
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 138
- Registration Number
- NCT00059475
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionChronic Phase Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT00004918
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 185
- Registration Number
- NCT00019682
- Locations
- 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Vaccination With Tetanus and KLH to Assess Immune Responses.
Terminated
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 112
- Registration Number
- NCT00000105
- Locations
- 🇺🇸
Division of Hematology, Oncology, and Transplantation 420 Delaware St., SE, Box 806 Mayo, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath